What is the purpose of this study?
To determine whether intratumoral injection of HSV1716, at dose levels shown to be safe for adult tumors, is safe in adolescents and young adults with non-CNS solid tumors.
Time Frame: Dose limiting toxicities will be assessed at 28 days after injection of HSV1716.
To measure antiviral immune response in patients with refractory cancer treated with HSV1716.
Time Frame: Antiviral immune response will be assessed 28 days after injection. Beginning at 1.5 years post injection, assessments will occur every 6 months. Beginning 5 years after the injection, assessments will occur annually until 15 years post injection.